Amanda Corbel
Manager, Communications Office
Email amanda.corbel@nih.gov or call 301-228-4489 for all media related questions.
Restoring the brake: Using molecular glues to fix a broken CRAF off-switch in Noonan Syndrome
Recent work suggests that molecular glues may provide both the selectivity for the NS-activated pathway and the generality to target the large majority of NS mutations.POSTED: 9/14/2026
Rethinking rare disease: How the ART Initiative is connecting genomics, the clinic, and the lab bench for RASopathies
The NCI ART Initiative is making headway in better understanding RASopathies and driving new therapies through cross-institutional collaboration.POSTED: 8/10/2026
Reproducibility in Science 2026
Scientists share key takeaways from the Reproducibility in Science Symposium, emphasizing important highlights for RAS researchers.POSTED: 7/27/2026
A defining moment for RAS medicine: Daraxonrasib delivers historic Phase 3 results in pancreatic cancer
Phase 3 study provides compelling evidence that direct RAS inhibition can translate into meaningful clinical benefit.POSTED: 6/16/2026
Seeing pancreatic cancer one cell at a time
Single-cell analysis reveals PDAC evolution is more complex than “KRAS-driven”—with diverse clones, variable dependence, and alternative pathways shaping tumors.POSTED: 5/11/2026
Vertical RAS Pathway Inhibition Creates a Ferroptosis-Prone State in Pancreatic Cancer
KRAS pathway inhibition rewires PDAC metabolism, increasing oxidative stress—and revealing a new vulnerability: ferroptosis as a strategy to overcome resistance.POSTED: 4/13/2026
KRAS primes the road for WNT-driven tumour initiation
New research reveals that activating KRAS mutations can quietly expand in normal colon tissue and prime cells for cancer, overturning the long‑held idea that APC loss must always be the first step in colorectal tumorigenesis.POSTED: 3/16/2026
A new way to break drug resistance in KRAS-mutant lung cancer: Restoring PP2A to re-sensitize tumors to RAS/MAPK inhibitors
Resistance to RAS/MAPK inhibitors isn’t just about runaway kinases—it’s about silenced phosphatases. In this JCI study, Dr. Goutham Narla shows that KRAS-mutant tumors evade therapy by disabling PP2A, and that pharmacologically restoring phosphatase activity rewires signaling, blocks resistance, and delivers durable responses.POSTED: 2/16/2026
Exosomes in personalized medicine for pancreatic cancer
Nature’s own delivery system meets precision oncology: the decade-long journey of engineered exosomes to a first-in-human KRAS trial.POSTED: 1/12/2026
LZTR1: How it recognizes, binds, and degrades RAS proteins
New structures reveal how LZTR1 recognizes inactive RAS proteins for degradation, opening a new path to therapeutically eliminate oncogenic KRAS.POSTED: 12/15/2025
Looking for more?
Explore our scientific publications
Our researchers publish hundreds of papers each year in various peer-reviewed journals, including Science, Nature, and The New England Journal of Medicine.